According to an article in the Financial Times, AstraZeneca (LSE: AZN, OMXS: AZN, NYSE: AZN) may be doing deals sooner rather than later. The newspaper interviewed R&D Chief Martin Mackay, who said he would be disappointed if the company didn’t strike several new agreements before the end of this year. The departure of long-time CEO David Brennan has not led to a change in R&D strategy, nor does it tie the hands of Mackay.
Just couple months ago Mackay clarified to Reuters the type of deals he is after and he remained consistent in saying that the deals may by full acquisitions of smaller quoted biotechs or licensing deals. There may also be different kind of arrangements, particularly when it comes to funding, such as those involving private equity firms, which could hint a little bit larger deals are a possibility too. Such would likely be in areas like diabetes and inflammation. Other than that, AstraZeneca is looking at a wide spectrum of candidates.
No comments:
Post a Comment